Private Practice for Orthopedics, Gaggenau, Germany.
Curr Med Res Opin. 2012 Aug;28(8):1313-21. doi: 10.1185/03007995.2012.709182. Epub 2012 Jul 19.
To investigate if the 180-mg diclofenac epolamine and heparin sodium 5600 IU medicated plaster (DHEP-heparin) is more effective for pain reduction in mild-to-moderate contusions than the reference diclofenac epolamine 180 mg plaster (DHEP).
This multicenter, multinational, prospective, double-blind versus reference comparator and versus placebo, controlled trial had balanced random assignment in three parallel treatment groups. The DHEP-heparin medicated plaster was compared to the DHEP medicated plaster and a placebo medicated plaster. A total of 331 outpatients, aged ≥18 and ≤65 years, with unilateral mild-to-moderate muscle contusion, pain on standardized movement of ≥50 mm, and superficial hematoma of ≤10 × 14 cm(2) completed the study. Plasters were applied each morning, for ≥20 hours daily for 14 consecutive days. Outcomes were assessed in three visits, over 14 days, plus patients' daily self-assessment.
05DCz/FHp11 - Eudra CT n: 2005-003829-31
Primary efficacy endpoint was mean change from baseline in pain on movement after 3 days of treatment, compared between groups. Secondary efficacy endpoints included mean daily change from baseline in pain on movement during treatment, pain level as assessed at control visits after 7 and 14 days, time (days) to hematoma disappearance based on patients' daily evaluations, rescue medication use, and overall treatment efficacy as judged by both patients and investigators.
Pain progressively declined in all groups, more rapidly in DHEP-heparin recipients, compared to DHEP, and in both active treatment groups compared to placebo. Adverse events were recorded in 24 of the 355 (6.7%) exposed patients, and generally resolved without need to interrupt treatment.
The DHEP-heparin plaster is superior to the reference DHEP plaster in reducing pain associated with mild-to-moderate muscle contusion. Both active treatments were significantly more effective than placebo, and each showed a comparably favorable, placebo-like safety profile.
研究 180mg 双氯芬酸依托泊苷和肝素钠 5600IU 贴剂(DHEP-肝素)是否比参比药物 180mg 双氯芬酸依托泊苷贴剂(DHEP)更能有效减轻轻度至中度挫伤的疼痛。
这项多中心、多国、前瞻性、双盲对照参比药物和安慰剂对照、平行分组的临床试验,在三个平行治疗组中进行了均衡随机分组。DHEP-肝素贴剂与 DHEP 贴剂和安慰剂贴剂进行了比较。共有 331 名年龄在 18 岁至 65 岁之间的门诊患者,单侧轻度至中度肌肉挫伤,标准化运动时疼痛≥50mm,浅表血肿≤10×14cm2,完成了这项研究。贴剂每天早上使用,每天至少 20 小时,连续使用 14 天。在 14 天内进行了 3 次就诊评估,加上患者的日常自我评估。
05DCz/FHp11 - Eudra CT n:2005-003829-31
治疗 3 天后,与基线相比,运动时疼痛的平均变化,组间比较。次要疗效终点包括治疗期间运动时疼痛的平均每日变化、第 7 天和第 14 天对照就诊时疼痛水平、基于患者日常评估的血肿消失时间、解救药物使用以及患者和研究者判断的整体治疗效果。
所有组的疼痛均逐渐减轻,DHEP-肝素组较 DHEP 组更快,且与安慰剂组相比,两治疗组均更快。在 355 名(6.7%)暴露患者中,有 24 名患者记录了不良事件,一般无需中断治疗即可解决。
DHEP-肝素贴剂在减轻轻度至中度肌肉挫伤引起的疼痛方面优于参比药物 DHEP 贴剂。两种活性治疗均明显优于安慰剂,且每种治疗的安全性与安慰剂相似。